BioSpace News Archive

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that the company will present at Piper Jaffray’s 31st Annual Healthcare Conference on Wednesday, December 4, 2019 at 11:00 am EST

Neon Therapeutics, Inc. (Nasdaq: NTGN) today announced its new strategic focus on the development of its novel neoantigen-based T cell programs, in conjunction with a corporate restructuring. Neon will focus its efforts on the advancement of both personal and precision neoantigen-targeted T cell therapy candidates.

Molecular Templates, Inc. (Nasdaq: MTEM) (the “Company” or “Molecular”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer, today announced that it has commenced an underwritten public offering of its common stock and newly designated Series A convertible preferred stock.

FDA Official Meeting Minutes Support Tonix’s Plan to file an Investigational New Drug (IND) Application in the First Quarter of 2020 for a Phase 2 Proof-of-Concept Study

A report from Milliman, Inc. about disparities between physical and behavioral healthcare for both in-network access and provider reimbursement rates underscores NABH’s position that unnecessary barriers continue to deny access to behavioral healthcare for patients who need it..

Universal Health Services, Inc. announced that its Board of Directors voted to pay a cash dividend of $0.20 per share on December 19, 2019 to shareholders of record as of December 5, 2019..

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the Piper Jaffray Healthcare Conference on Wednesday, December 4, 2019, at 2:30 p.m. EST in New York City.

Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has completed its acquisition of Celgene Corporation (NASDAQ:CELG) following the receipt of regulatory approval from all government authorities required by the merger agreement and, as announced on April 12, 2019, approval by Bristol-Myers Squibb and Celgene stockholders.

Celgene Corporation announced that following the completion of Celgene’s acquisition by Bristol-Myers Squibb Company, Bristol-Myers Squibb and Celgene plan to transfer the listing of Celgene’s contingent value rights that are related to Celgene’s ABRAXANE® product from the NASDAQ Global Market to the New York Stock Exchange

European Patent EP3004337 Upheld by the EPO in Favor of Cellectis, Refers to the Method of Preparing T-Cells for Immunotherapy Using the RNA-Guided CRISPR-Cas9 Nuclease System